Major Diseases

KIDNEY STONE

  • 12% in a total population reported to be prone to urinary stones.

  • The lifetime risk of developing kidney stones is one in 10 for men andone in 35 for women.

  • 50% of the population are severely affected by renal damage.

HEART DISEASE

In a regular private hospital, the cost of an open heart surgery ranges
from Rs 1.75 lakh to 4.25 lakh. Coronary angiography is likely to cost
one around Rs. 10,000 to Rs. 15,000.

  • Types
  • Coronary Artery Disease (CAD)
  • Heart Arrhythmias.
  • Heart Failure.
  • Heart Valve Disease.
  • Pericardial Disease.
  • Cardiomyopathy (Heart Muscle Disease)
  • Congenital Heart Disease.

CANCER

  • The projected incidence of patients with cancer in India among males was
    679,421 (94.1 per 100,000) and among females 712,758 (103.6 per
    100,000) for the year 2020.
  • The projected incidence of patients with cancer in India
    among males was 679,421
  • (94.1 per 100,000) and among
  • Females 712,758 (103.6 per 100,000)
  • Estimated number of people living with the disease: around 2.25 million

  • Every year, new cancer patients registered: Over 11,57,294 lakhCancer-related deaths: 7,84,821 Risk of developing cancer before the age of 75 years

TUBERCULOSIS

According to World Health Organization (WHO) estimates, India has the
world’s largest tuberculosis epidemic. In 2020, India accounted for 26%
of the incident TB cases across the globe. India has incidence rate of
192 cases per 100,000 of population.

The WHO TB statistics for India for 2021 give an estimated incidence
figure of 2,590,000 million cases.

AIDS

  • The total number of people living with HIV (PLHIV) in India was estimated
    at 23.19 lakh (18.33 lakh– 29.78 lakh) in 2021.
  • According to the report, Maharashtra was estimated to have the highest number
    of people living with HIV at 3.96 lakh, followed by Andhra Pradesh at 3.14 lakh,
    Karnataka at 2.69 lakh.
  • COST
  • The cost of antiretroviral therapy (ART) used to treat HIV is the cheapest in
    India, with first-line treatment costing the government Rs 5,000/person/year, and
    second-line therapy – for people with immunity against the first-line drugs –
    priced at Rs 29,000/person/year.